Xeris Pharmaceuticals, Inc. (XERS) News
Filter XERS News Items
XERS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XERS News Highlights
- For XERS, its 30 day story count is now at 3.
- Over the past 7 days, the trend for XERS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about XERS are DRUG.
Latest XERS News From Around the Web
Below are the latest news stories about XERIS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate XERS as an investment opportunity.
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceCHICAGO, December 27, 2023--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time. To access the presentation, please visit "Events" |
11 High Growth Micro-Cap Stocks to BuyIn this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. Shares of small companies with market capitalization usually between $50 to $300 million are considered micro-cap stocks. The risk in these investments […] |
My Top Small-Cap Stock Pick for 2024 Is a Biotech With a Big OpportunityIt is that time of year when market strategists and pundits roll out their predictions and stock picks for the year ahead. This may be done to extend patent life or to produce a more convenient way to deliver the drug. |
President & COO of Xeris Biopharma Holdings Picks Up 7.5% More StockEven if it's not a huge purchase, we think it was good to see that John Shannon, the President & COO of Xeris Biopharma... |
Xeris Biopharma CEO unveils game-changing drug innovations and record financial successXeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on the company's focus on innovative drug formulation technology after reporting strong third-quarter results. |
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2023 Earnings Call TranscriptXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Hello, everyone and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno. I’ll be operating your call today. [Operator Instructions] I will now hand over to your host, Allison Wey, Senior Vice President of Investor […] |
Q3 2023 Xeris Biopharma Holdings Inc Earnings CallQ3 2023 Xeris Biopharma Holdings Inc Earnings Call |
I've Prescribed Myself This Biotech Stock to Get Through the Market MessHere's why I'm buying this small-cap name, despite the risk of chasing after earnings reports right now. |
Xeris Biopharma Holdings Inc (XERS) Reports Substantial Revenue Growth in Q3 2023Financial Highlights Reflect Strong Sales and Progress Towards Cash Flow Breakeven |
Xeris Biopharma Reports Third Quarter 2023 Financial ResultsCHICAGO, November 09, 2023--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2023 and corporate highlights. |